ARTICLE | Clinical News

MP0112: Phase I/IIa data

May 9, 2011 7:00 AM UTC

Top-line data from a dose-escalation European Phase I/IIa trial in 32 patients showed that a single intravitreal injection of MP0112 was well tolerated. Additionally, the therapeutic effect of MP0112 increased in a dose-dependent manner, with the high dose showing an effect beyond 16 weeks in most patients. Data were presented at the Association for Research in Vision and Ophthalmology meeting in May in Fort Lauderdale. ...